# T-Cypher Bio Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/t-cypher-bio-holdings

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.tcypherbio.com
- Total disclosed funding: $4M
- Latest round: Seed (Oct 22, 2021)
- Investors on record: 4

## About

Based in Oxfordshire, UK, and founded in 2020, T-Cypher Bio Holdings Limited operates as a healthcare-based company providing treatment of autoimmune, inflammatory, and infectious diseases through TCR-based therapeutics. In Dec 2020, T-Cypher Bio Holdings Limited raised seed funding from Oxford Science Enterprises. As of 2023, Thomas Lars Andresen operates as a Chief Executive Officer of T-Cypher Bio Holdings Limited.

T-Cypher Bio Holdings Limited developed therapeutics, diagnostics, and technologies for supporting and improving the medical industries. The company offers T-cell receptor (TCR) therapies for the treatment of solid tumors, autoimmune, inflammatory, and infectious diseases. In addition, the firm’s technology provides identifies T-cell clones directly from disease tissues using target screening libraries.

## Funding rounds

- Seed, Oct 22, 2021, $4M — Borealis Ventures, University of Oxford, Oxford Sciences Enterprises, RT Ventures

## Investors

- Borealis Ventures (https://capitalatlas.ai/funds/borealis-ventures) — Seed
- University of Oxford — Seed
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed
- RT Ventures — Seed